Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis.
Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Dig Dis Sci. 2012 Feb; 57(2):472-80.